<DOC>
	<DOCNO>NCT01237119</DOCNO>
	<brief_summary>The purpose study investigate whether 48 week treatment once-daily injection liraglutide improve liver disease ( liver fat , inflammation scar ) relate metabolic parameter overweight patient nonalcoholic steatohepatitis , enough warrant investigation .</brief_summary>
	<brief_title>Liraglutide Efficacy Action Non-Alcoholic Steatohepatitis</brief_title>
	<detailed_description>Non-alcoholic fatty liver disease ( NAFLD ) responsible increase prevalence liver disease become common cause liver disease western world . NAFLD recognise hepatic manifestation metabolic syndrome , cluster metabolic abnormality characterise abdominal obesity , insulin resistance , impair glucose metabolism , hypertension dyslipidaemia . In mild form accumulation fat liver ( steatosis ) without liver damage , however many case progress non-alcoholic steatohepatitis ( NASH ) , cirrhosis . Current treatment option NASH limit efficacy , necessitate development effective option . New agent Glucagon-like Peptide-1 ( GLP-1 ) agonists improve diabetic control facilitate weight loss suggest therapy NASH . No published study date assess impact GLP-1 agonist , Liraglutide , liver histology metabolism obese patient NASH . This study hypothesise treatment liraglutide result significant improvement histological disease activity overweight patient NASH , presence absence Type 2 Diabetes ( T2DM )</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>NASH liver biopsy ( within 6 month screen visit ) . NAFLD Activity Score ( NAS ) ≥ 3 , comprise minimum 1 point individual steatosis , lobular inflammation hepatocyte ballooning score Body Mass Index ( BMI ) ≥ 25 randomisation Type 2 Diabetes Mellitus/impaired glucose tolerance normal glucose tolerance Exclusion Criteria ( brief ) : Insulin dependent diabetes Glycosylated Haemoglobin ( HbA1c ) &gt; 9.0 % treatment dipeptidyl peptidase 4 ( DPPIV ) inhibitor , Glucagonlike Peptides ( GLP ) 1 analogue , thiazolidinediones ( TZDs ) Past Medical History Acute ( chronic ) pancreatitis/pancreatic carcinoma , weight loss surgery , liver transplantation , Medullary thyroid cancer , hepatocellular carcinoma ( HCC ) , Multiple Endocrine Neoplasia ( MEN ) syndrome , malignancy ( within last 3 year , exception treat skin malignancy ) Other liver aetiology ( i.e . druginduced , viral hepatitis , autoimmune hepatitis , primary biliary cirrhosis , primary sclerosing cholangitis , haemochromatosis , alpha 1 antitrypsin deficiency , Wilsons disease ) concomitant recent use orlistat , prednisolone , Refusal lack capacity give inform consent participate trial Participation clinical trial investigational therapy agent within 3 month randomisation Patient ( carer ) deem competent use correct site technique subcutaneous injection trial treatment ( contain dummy drug practice ) visit 2 NAS &lt; 3 Child 's B C cirrhosis Abnormal clinical examination thyroid ( i.e . unexplained goitre palpable nodule ) Liver enzymes &gt; 10 x upper limit normal Average alcohol consumption per week &gt; 21 unit ( 210g ) male , &gt; 14 unit ( 140g ) female within last 5 year . &gt; 5 % weight loss since diagnostic liver biopsy obtain . Recent concomitant use steroid ( oral ) , methotrexate , amiodarone , Orlistat Addition significant change ( judged chief investigator ) dose follow drug ; Angiotensin convert enzyme ( ACE ) inhibitor , Angiotensin receptor blocker ( ARBs ) and/or Multivitamins ( contain Vitamin E ) Known positivity antibody Human Immunodeficiency virus ( HIV ) Serum creatinine &gt; 150 μmol/L currently treat renal replacement therapy Past medical history multiple drug allergy ( define anaphylactoid drug reaction &gt; 2 drug group ) Presence acute/chronic infection illness discretion chief investigator might compromise patient 's health safety trial Pregnancy breastfeed Women , childbearing age , willing practise effective contraception ( i.e . barrier , oral contraceptive pill , implanon history hysterectomy ) 48 week duration trial onemonth last administration drug . Men , sexually active woman childbearing age , willing practise effective contraception 48 week duration trial onemonth last administration drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>